About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Expecting? How getting vaccinated while pregnant can help protect newborns from RSV

(BPT) - Expecting mothers have countless preparations to make before their little ones arrive, from decorating the nursery and installing a car seat to picking a pediatrician and thinking about maternal immunizations. For mom and actress Chloe Bridges, who is partnering with Pfizer, navigating pregnancy - and the choices that come along with it - was a little overwhelming.

"Looking back, I was facing so many decisions about how to help protect my baby. Everyone - my friends, my parents, my husband Adam's parents, social media - had their own opinions," said Bridges. "It was a lot."

Now, when reflecting on her pre-birth planning, Bridges says she has 'new mom clarity.' One crucial decision she made during pregnancy was receiving ABRYSVO® (Respiratory Syncytial Virus Vaccine), the only vaccine given to pregnant people at 32 through 36 weeks gestation to help protect infants from the risk of severe respiratory syncytial virus (RSV) from birth through six months.

What is RSV?

RSV is a highly contagious virus that can be dangerous for babies. In fact, RSV is the leading cause of hospitalization in infants in the U.S, with more than 50% of all RSV-related hospitalizations during the first year of life occurring within the first three months, and more than 75% occurring within the first six months.

The role of maternal immunization

During pregnancy, the mother's body naturally passes antibodies, including those her body creates after receiving a vaccine, to the infant. That means mothers who are between 32 and 36 weeks pregnant can help protect their babies from the risk of RSV starting with their first breath by receiving the ABRYSVO vaccine.

"Expecting mothers are doing everything they can to prepare for the birth of their babies. It's such a transformative and life-changing experience to have a baby," said Bridges. "For me, speaking with my OB-GYN throughout my pregnancy journey helped me to make decisions that were right for me and Beau. She answered all my questions and provided me with so much information that I needed to prepare."

Mother holding her adorable 32 week-old child.

An important maternal vaccine

If you're pregnant and approaching the third trimester of pregnancy, consider asking your OB-GYN or other healthcare provider about ABRYSVO. Pfizer's ABRYSVO is the first and only maternal RSV vaccine that helps protect newborns against RSV from birth through six months of age. To avoid the potential risk of preterm birth, ABRYSVO should be given at 32 through 36 weeks gestational age.

The Centers for Disease Control and Prevention (CDC) recommends ABRYSVO if you are 32 through 36 weeks pregnant from September through January (in most parts of the continental United States). Keep in mind that the recommended months for maternal vaccination might vary depending on your location.

Decide what's best for you and your baby

"I wanted to help protect Beau from RSV from his first breath," said Bridges. "I'm so glad I decided to get the vaccine for him while I was pregnant."

Talk to your OBGYN or other healthcare provider to learn more about how to help protect your baby against RSV.

This article was sponsored by Pfizer. To learn more about the vaccine and deepen your knowledge about RSV and maternal immunization, visit ABRYSVO.com.

Important Safety Information and Use

WHAT IS ABRYSVO?

ABRYSVO is a vaccine indicated for pregnant individuals at 32 through 36 weeks gestational age for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age.

  • ABRYSVO should not be given to anyone with a history of severe allergic reaction (e.g., anaphylaxis) to any of its components
  • To avoid the potential risk of preterm birth, ABRYSVO should be given at 32 through 36 weeks gestational age
  • Fainting can happen after getting injectable vaccines, including ABRYSVO. Precautions should be taken to avoid falling and injury due to fainting
  • Adults with weakened immune systems, including those receiving medicines that suppress the immune system, may have a reduced immune response to ABRYSVO
  • Vaccination with ABRYSVO may not protect all people
  • In pregnant individuals, the most common side effects (≥ 10%) were pain at the injection site, headache, muscle pain, and nausea
  • In clinical trials where ABRYSVO was compared to placebo, infants born to pregnant individuals experienced low birth weight (5.1% ABRYSVO versus 4.4% placebo) and jaundice (7.2% ABRYSVO versus 6.7% placebo)

Ask your healthcare provider about the risks and benefits of ABRYSVO. Only a healthcare provider can decide if ABRYSVO is right for you. Always talk to your healthcare provider about any side effects you may experience.

You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Individuals who received ABRYSVO during pregnancy are encouraged to enroll in a pregnancy exposure registry at 1-800-616-3791. The registry will monitor pregnancy outcomes.

Please see full Prescribing Information for ABRYSVO.

PP-A1G-USA-1849 © 2024 Pfizer Inc. All rights reserved. November 2024.

Expectant mothers have countless preparations to make before their little ones arrive, from decorating the nursery and installing a car seat to picking a pediatrician. For mom and actress Chloe Bridges, navigating pregnancy - and the choices that come along with it - was a little overwhelming.

"Looking back, I was facing so many decisions about how to help protect my baby. Everyone - my friends, my parents, my husband Adam's parents, social media - had their own opinions," said Bridges. "It was a lot."

Now, when reflecting on her pre-baby planning, Bridges says she has 'new mom clarity.' One crucial decision she made during pregnancy was receiving ABRYSVO, the only maternal vaccine approved to help protect her son Beau from the risk of severe respiratory syncytial virus (RSV) for the first six months of his life.1

What is RSV?

RSV is a highly contagious virus that can be dangerous for babies. In fact, a study published in Infectious Diseases and Therapy journal, RSV is the leading cause of hospitalization in infants in the U.S, with more than 50% of all RSV-related hospitalizations during the first year of life occurring within the first three months, and more than 75% occurring within the first six months.2

The role of maternal immunization

During pregnancy, the mother's body naturally passes antibodies, including those her body creates after receiving a vaccine, to the infant.3 That means mothers who are between 32 and 36 weeks pregnant can help protect their babies from the risk of RSV before their first breath by receiving the ABRYSVO vaccine.

"Expecting mothers are doing everything they can to prepare for the birth of their babies. It's such a transformative and life-changing experience to have a baby," said Bridges. "For me, speaking with my OB-GYN throughout my pregnancy journey helped me to make decisions that were right for me and Beau. She answered all my questions and provided me with so much information that I needed to prepare."

An important maternal vaccine

If you're pregnant and approaching the third trimester of pregnancy, consider asking your doctor about ABRYSVO® (Respiratory Syncytial Virus Vaccine). Pfizer's ABRYSVO is the first and only RSV vaccine that helps protect newborns against RSV from birth through six months of age.

The Centers for Disease Control and Prevention (CDC) recommends ABRYSVO if you are 32 through 36 weeks pregnant, from September through January (in most parts of the U.S.).4 Keep in mind that the recommended months for maternal vaccination might vary depending on your location.

Decide what's best for you and your baby

"I wanted to help protect Beau from RSV at first breath," said Bridges. "I'm so glad I decided to get the vaccine for him while I was pregnant."

Talk to your OBGYN or other healthcare provider to learn more about how to help protect your baby against the risk of RSV.

To learn more about the vaccine and deepen your knowledge about RSV and maternal immunization, visit ABRYSVO.com.

1. [PLACEHOLDER]

2. Parikh, Rohan C, Kimmie K McLaurin, Andrea V Margulis, Josephine Mauskopf, Christopher S Ambrose, Melissa Pavilack, and Sean D Candrilli. 2017. "Chronologic Age at Hospitalization for Respiratory Syncytial Virus among Preterm and Term Infants in the United States." Infectious Diseases and Therapy 6 (4): 477-86. https://pubmed.ncbi.nlm.nih.gov/28866800/.

3. [PLACEHOLDER]

4. CDC. "Immunizations to Protect Infants." Respiratory Syncytial Virus Infection (RSV), 2024, www.cdc.gov/rsv/vaccines/protect-infants.html.

Important Safety Information and Uses

  • ABRYSVO should not be given to anyone with a history of severe allergic reaction (e.g., anaphylaxis) to any of its components
  • To avoid the potential risk of preterm birth, ABRYSVO should be given at 32 through 36 weeks gestational age
  • Fainting can happen after getting injectable vaccines, including ABRYSVO. Precautions should be taken to avoid falling and injury due to fainting
  • Adults with weakened immune systems, including those receiving medicines that suppress the immune system, may have a reduced immune response to ABRYSVO
  • Vaccination with ABRYSVO may not protect all people
  • In pregnant individuals, the most common side effects (≥ 10%) were pain at the injection site, headache, muscle pain, and nausea
  • In clinical trials where ABRYSVO was compared to placebo, infants born to pregnant individuals experienced low birth weight (5.1% ABRYSVO versus 4.4% placebo) and jaundice (7.2% ABRYSVO versus 6.7% placebo)

Ask your healthcare provider about the risks and benefits of ABRYSVO. Only a healthcare provider can decide if ABRYSVO is right for you. Always talk to your healthcare provider about any side effects you may experience.

You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Individuals who received ABRYSVO during pregnancy are encouraged to enroll in a pregnancy exposure registry at 1-800-616-3791. The registry will monitor pregnancy outcomes.

Please see full Prescribing Information for ABRYSVO.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.